New pages

Jump to navigation Jump to search
New pages
Hide registered users | Hide bots | Show redirects
  • 03:47, 21 April 2024 ‎BRENZAVVY- bexagliflozin (hist | edit) ‎[12,281 bytes] ‎Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=BRENZAVVY- bexagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=treatment |indication=glycemic control in adults with type 2 diabetes mellitus |hasBlackBoxWarning=Yes |adverseReactions=female genital mycotic infections, urinary tract infection and increased urination |blackBoxWarningTitle=Warnings |blackBoxWarningBody=*Not re...")
  • 16:30, 19 April 2024 ‎Sparsentan (hist | edit) ‎[8,644 bytes] ‎Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi[mailto:k.doraghi@yahoo.com] |genericName=sparsentan |aOrAn=an |drugClass=endothelin and angiotensin II receptor antagonist |indicationType=treatment |indication=proteinuria(reduce) in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g |hasBlackBoxWarning=Yes |adverseReactions=Hepatotoxicity, Embryo-Fetal Tox...")
  • 19:33, 17 April 2024 ‎SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY (hist | edit) ‎[2,387 bytes] ‎Hafiza Amna Qadeer (talk | contribs) (Created blank page)
  • 08:08, 17 April 2024 ‎Elranatamab-bcmm (hist | edit) ‎[32,900 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:08, 17 April 2024 ‎Palovarotene (hist | edit) ‎[39,234 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:08, 17 April 2024 ‎Pozelimab-bbfg (hist | edit) ‎[2,443 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:07, 17 April 2024 ‎Motixafortide (hist | edit) ‎[26,106 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:07, 17 April 2024 ‎Momelotinib (hist | edit) ‎[34,123 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:06, 17 April 2024 ‎Cipaglucosidase alfa-atga (hist | edit) ‎[38,322 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:05, 17 April 2024 ‎Etrasimod (hist | edit) ‎[53 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:05, 17 April 2024 ‎Zilucoplan (hist | edit) ‎[53 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:04, 17 April 2024 ‎Bimekizumab (hist | edit) ‎[53 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:04, 17 April 2024 ‎Vamorolone (hist | edit) ‎[53 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:04, 17 April 2024 ‎Mirikizumab-mrkz (hist | edit) ‎[53 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:03, 17 April 2024 ‎Toripalimab-tpzi (hist | edit) ‎[53 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:02, 17 April 2024 ‎Fruquintinib (hist | edit) ‎[25,648 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F...")
  • 07:52, 17 April 2024 ‎Taurolidine, heparin (hist | edit) ‎[9,993 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients...")
  • 07:43, 17 April 2024 ‎Repotrectinib (hist | edit) ‎[32,783 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru...")
  • 07:32, 17 April 2024 ‎Efbemalenograstim alfa-vuxw (hist | edit) ‎[20,126 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle....")
  • 05:50, 16 April 2024 ‎Capivasertib (hist | edit) ‎[34,175 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based...")
  • 05:27, 16 April 2024 ‎Iptacopan (hist | edit) ‎[33,311 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody=<span style="clear;"> FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me...")
  • 07:24, 15 April 2024 ‎Vutrisiran (hist | edit) ‎[17,228 bytes] ‎Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=vutrisiran |aOrAn=a |drugClass=transthyretin-directed small interfering RNA |indicationType=treatment |indication=polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=pain in extremity, arthralgia, dyspnea, and decreased vitamin A levels. |fdaLIADAdult=Recommended Dosage The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous inj...")
  • 09:51, 27 March 2024 ‎Bismuth subnitrate (hist | edit) ‎[4,643 bytes] ‎Imam Ali Shah (talk | contribs) (Created page with "dasda") Tag: Visual edit
Retrieved from "https://www.wikidoc.org/index.php/Special:NewPages"